Blog
RSS FeedPosted by Michael Wonder on 30 Jul 2020
Health Canada Approves Brivlera (brivaracetam) to treat partial-onset seizures in paediatric epilepsy patients
29 July 2020 - Health Canada's approval of Brivlera provides paediatric epilepsy patients with a treatment option which can be initiated ...
Posted by Michael Wonder on 28 Jul 2020
Health Canada grants marketing authorisation with conditions for Gilead's Veklury (remdesivir) for the treatment of coronavirus disease 2019 (COVID-19)
28 July 2020 - Veklury is the first approved treatment option for COVID-19 in Canada. ...
Posted by Michael Wonder on 23 Jul 2020
Spravato (esketamine) nasal spray is available for Canadian patients
22 July 2020 - A new anti-depressant with a novel mechanism of action to treat major depressive disorder in adults. ...
Posted by Michael Wonder on 17 Jul 2020
Xenleta (lefamulin) receives Health Canada approval for treatment of community acquired pneumonia
16 July 2020 - Nabriva Therapeutics announced today that its partner, Sunovion Pharmaceuticals, has received approval from Health Canada to market ...
Posted by Michael Wonder on 09 Jul 2020
Sarclisa (isatuximab for injection) now available in Canada for patients with relapsed and refractory multiple myeloma
8 July 2020 - First and only anti-CD38 antibody in combination with pomalidomide and dexamethasone to be approved in Canada. ...
Posted by Michael Wonder on 09 Jul 2020
Astex Pharmaceuticals, Taiho Oncology and Otsuka Pharmaceutical announce Health Canada approval of Inqovi (decitabine and cedazuridine) tablets, oral hypomethylating agent therapy for intermediate and high-risk MDS and C
7 July 2020 - Inqovi is the first orally administered hypomethylating agent approved by the FDA and Health Canada. ...
Posted by Michael Wonder on 23 Jun 2020
Deciphera announces Health Canada’s authorisation of Qinlock (ripretinib) for the treatment of fourth-line gastro-intestinal stromal tumour
22 June 2020 - Qinlock significantly improved progression-free survival and showed clinically meaningful overall survival in global INVICTUS Phase 3 study. ...
Posted by Michael Wonder on 17 Jun 2020
Health Canada Approves Xtandi (enzalutamide) for the treatment of metastatic castration-sensitive prostate cancer
16 June 2020 - Xtandi is the first and only androgen receptor-axis-targeted therapy approved by Health Canada in three clinical ...
Posted by Michael Wonder on 15 Jun 2020
Sunovion announces Health Canada approval of Kynmobi (apomorphine hydrochloride) soluble film for the treatment of Parkinson's disease OFF episodes
15 June 2020 - First and only sublingual therapy approved for the on-demand treatment of Parkinson’s disease OFF episodes. ...
Posted by Michael Wonder on 12 Jun 2020
Health Canada issues notice of compliance for Bausch Health's Duobrii
11 June 2020 - Topical combination improving the sings and symptoms of plaque psoriasis in adult patients with moderate to ...
Posted by Michael Wonder on 10 Jun 2020
Sandoz Canada receives Health Canada approval to launch two oncology biosimilars: Ziextenzo and Riximyo
9 June 2020 - These two approvals mark an important milestone for Sandoz Canada, bringing its biosimilars into oncology at a ...
Posted by Michael Wonder on 28 May 2020
Health Canada approves birth control arm implant Nexplanon
26 May 2020 - A popular birth control implant that has long been advocated for use in Canada has now ...
Posted by Michael Wonder on 26 May 2020
Ofev (nintedanib) now available in Canada for adults living with progressive fibrosing interstitial lung diseases
25 May 2020 - Ofev slowed lung function decline in PF-ILD patients by 57% compared to placebo. ...
Posted by Michael Wonder on 06 May 2020
AbbVie receives Health Canada approval for the combination of Venclexta (venetoclax) with obinutuzumab for patients with previously untreated chronic lymphocytic leukaemia
5 May 2020 - Venclexta (venetoclax) plus obinutuzumab is the first chemotherapy-free, fixed-duration combination regimen approved by Health Canada for patients ...
Posted by Michael Wonder on 30 Apr 2020
Teva Canada announces the launch of Ajovy for the preventive treatment of migraine in adults who have at least four migraine days per month
29 April 2020 - Ajovy is the first and only anti-CGRP treatment with both quarterly and monthly dosing for the preventive ...